Resistin Serum Levels Are Increased but Not Correlated with Insulin Resistance in Chronic Hemodialysis Patients

2005 ◽  
Vol 23 (6) ◽  
pp. 421-428 ◽  
Author(s):  
Georgios Filippidis ◽  
Vasilios Liakopoulos ◽  
Peter Rene Mertens ◽  
Theodoros Kiropoulos ◽  
Nikolaos Stakias ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis

scholarly journals Effect of short-term erythropoietin therapy on insulin resistance and serum levels of leptin and neuropeptide Y in hemodialysis patients

2017 ◽  
Vol 21 (5) ◽  
pp. 724 ◽  
Author(s):  
OsamaA Khamis ◽  
HamedM Osman ◽  
MohamedS Elfeky ◽  
AmaniM El Amin Ali ◽  
MostafaY Abdelwahed
Keyword(s):  
Insulin Resistance ◽  
Neuropeptide Y ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Short Term

scholarly journals Insulin Resistance and Protein Metabolism in Chronic Hemodialysis Patients

2013 ◽  
Vol 23 (3) ◽  
pp. e59-e66 ◽  
Author(s):  
Serpil M. Deger ◽  
Mary B. Sundell ◽  
Edward D. Siew ◽  
Phyllis Egbert ◽  
Charles D. Ellis ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Protein Metabolism ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis

scholarly journals Lipoprotein (a) as an Acute Phase Reactant in Patients on Chronic Hemodialysis

2010 ◽  
Vol 10 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Valdete Topçiu-Shufta ◽  
Luljeta Begolli ◽  
Emrush Kryeziu
Keyword(s):  
Serum Albumin ◽  
Acute Phase ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Acute Phase Reactant ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Atherosclerotic Cardiovascular Disease ◽  
Normal Range ◽  
Lipoprotein A

Lipoprotein (a) [Lp(a)], is an independent risk factor for atherosclerotic cardiovascular disease in patients on chronic hemodialysis. A low concentration of high density lipoprotein cholesterol (HDL-C) and serum albumín are another potential risk factors. The purpose of this study was to explore in patients on chronic hemodialysis, whether Lp(a) elevated levels are influenced by activated acute phase response (APR) and the correlation of Lp(a) with HDL-C and serum albumin. In 69 hemodialysis patients with C-reactive protein (CRP) levels over than 10 mg/L and 101 hemodialysis patients with CRP levels in the normal range, Lp(a), HDL-C and serum albumin were determined in relation to CRP, as a sensitive marker of an APR. Results showed that serum concentration of CRP in 69 hemodialysis patients was significantly higher than in controls (44,62 mg/L versus 8,75 mg/L, p<0,01). Patients with elevated CRP had significantly higher serum levels of Lp(a) and lower serum levels of HDL-C and albumin, than patients with CRP in the normal range (35,39 mg/dl versus 28,6 mg/dl, p<0,01, 0,91 mmol/L versus 1,29 mmol/L, p<0,01 and 33,56 g/L versus 35,86 g/L, p<0,01). Lp(a) levels correlated positively with CRP and negatively with HDL-C and serum albumin, in patients with elevated CRP, but not in healthy controls. According to the results Lp(a) reacts as an acute phase protein, in patients with APR.

P1270INCREASED SCLEROSTIN, BUT NOT DKK-1 PROTEIN, IS ASSOCIATED WITH ELEVATED PULSE WAVE VELOCITY IN HEMODIALYSIS SUBJECTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
EIRINI STAVRINOU ◽  
Panteleimon Sarafidis ◽  
Charalampos Koumaras ◽  
Charalampos Loutradis ◽  
Panagiotis Giamalis ◽  
...  
Keyword(s):  
Arterial Stiffness ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Applanation Tonometry ◽  
Chronic Hemodialysis ◽  
Large Set ◽  
Vascular Changes

Abstract Background and Aims Sclerostin and Dickkopf-1 (Dkk-1) protein are inhibitors of the canonical Wnt/β-catenin bone pathway. Pilot data suggest that sclerostin may be involved in vascular changes in CKD, but data on Dkk-1 effects are scarce. This is the first study investigating simultaneously the associations of sclerostin and Dkk-1 with arterial stiffness in hemodialysis patients. Method 80 patients on chronic hemodialysis had carotid-femoral pulse wave velocity (PWV), central BP and wave reflections evaluated with applanation tonometry (Sphygmocor) in a mid-week non-dialysis day. Serum levels of sclerostin and Dkk-1 were measured with ELISA. A large set of demographic, co-morbid, laboratory and drug parameters were used in the analyses. Results Subjects with PWV&gt;9.5 m/sec (high arterial stiffness group, n=40) were older, had higher BMI, higher prevalence of hypertension, diabetes and coronary-heart-disease and higher peripheral SBP, central SBP, C- reactive protein and serum sclerostin (p=0.02), but similar Dkk-1 compared to subjects with low PWV. When dichotomizing the population by sclerostin levels, those with high sclerostin had higher PWV than patients with low sclerostin levels (10.63±2.71 vs 9.77±3.13, p=0.048). Increased sclerostin (&gt;200 pg/ml) was significantly associated with increased PWV (&gt;9.5 m/s) (HR:2.778, 95%CI:1.123-6.868, per pg/ml increase); this association remained significant after stepwise adjustment for Dkk-1, iPTH and calcium x phosphate product. In contrast, no association was noted between Dkk-1 and PWV (HR: 1.000, 95%CI: 0.416-2.403). Conclusion Serum sclerostin is associated with PWV independently of routine markers of CKD-MBD in hemodialysis patients. In contrast Dkk-1 has no association with arterial stiffness and is rather not pathophysiologically involved in relevant vascular changes.

Beta-2 Microglobulin in Peritoneal Dialysis Patients: Serum Levels and Peritoneal Clearances

1988 ◽  
Vol 8 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Carol R. DiRaimondo ◽  
Patricia McCarley ◽  
William J. Stone
Keyword(s):  
Peritoneal Dialysis ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Bone Lesions ◽  
Dialysis Patients ◽  
Urea Nitrogen ◽  
Pathologic Fractures ◽  
Beta 2 ◽  
Beta 2 Microglobulin

Beta-2 microglobulin (B2M) is amyloidogenic in long-term hemodialysis patients, with amyloid deposition manifesting as lytic bone lesions, carpal tunnel syndrome, destructive arthropathies, tenosynovitis, and pathologic fractures. To study the behavior of this protein in the peritoneal dialysis population, serum levels of B2M from 14 chronic peritoneal dialysis (CPD) patients (4IPD, 10 CAPD) were compared to those of 15 chronic hemodialysis patients, and peritoneal clearances were measured in 9 CAPD patients. Standard cuprophan dialyzers were used for hemodialysis. Serum B2M levels were significantly lower in the peritoneal dialysis group (mean ± SD 73.2 ± 20.9 mg/L) than in the hemodialysis group (100.3 ± 24.7 mg/L, p < .004). When CAPD patients alone were compared to the hemodialysis patients, lower serum B2M levels were again apparent, with mean 68.7 ± 16.4 mg/L (p ≤ .002). Mean serum B2M in IPD patients (84.6 ± 28.9 mg/L) did not differ statistically from either the CAPD or the hemodialysis group. Peritoneal clearance of B2M, urea nitrogen, and creatinine over a 6 h exchange were obtained in 9 CAPD patients without peritonitis. Mean clearance (±SD) of B2M was 0.9 ± 0.4 ml/min/1.73 m2, urea nitrogen 5.3 ± 0.3 ml/min/1.73 m2, and creatinine 4.2 ± 0.8 ml/min/1.73 m2. Mean loss of B2M via the peritoneal cavity was 19.9 ± 6.6 mg/2 L-exchange/1.73 m2 (range 7.7 to 26.2 mg/2 L-exchange/1.73 m2). Decreased serum B2M in peritoneal dialysis patients is consistent with increased clearance by the peritoneal membrane versus standard cellulosic hemodialysis membranes. Whether use of CPD rather than hemodialysis can prevent or even treat dialysis-associated amyloidosis (AB2M) remains speculative.

Sign in / Sign up

Export Citation Format

Share Document